Sionna Therapeutics (SION) – Research Analysts’ Weekly Ratings Changes

Sionna Therapeutics (NASDAQ: SION) recently received a number of ratings updates from brokerages and research firms:

• 12/8/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Sionna Therapeutics had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.
• 11/25/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Sionna Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $50.00 price target on the stock.
• 11/18/2025 – Sionna Therapeutics was upgraded by analysts at BTIG Research to a “strong-buy” rating.
• 11/15/2025 – Sionna Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/13/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/5/2025 – Sionna Therapeutics had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc..

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Ra Capital Management, L.P. sold 25,183 shares of Sionna Therapeutics stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $39.50, for a total transaction of $994,728.50. Following the completion of the sale, the director directly owned 159,033 shares in the company, valued at approximately $6,281,803.50. The trade was a 13.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Peter A. Thompson sold 1,600 shares of Sionna Therapeutics stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $44.49, for a total value of $71,184.00. Following the transaction, the director owned 3,596,886 shares of the company’s stock, valued at $160,025,458.14. The trade was a 0.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 1,604,841 shares of company stock valued at $58,312,100. 3.90% of the stock is currently owned by corporate insiders.

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.